These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 34465135)

  • 1. Real-World Experience with Two-Drug Regimens in HIV-1-Infected Patients Beyond the Indication of Clinical Trials: 48 Weeks' Results.
    Arancón Pardo A; Moreno Palomino M; Jiménez-Nácher I; Moreno F; González Fernández MÁ; González-García J; Herrero Ambrosio A
    AIDS Res Hum Retroviruses; 2021 Oct; 37(10):761-767. PubMed ID: 34465135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort.
    Fabbiani M; Rossetti B; Ciccullo A; Oreni L; Lagi F; Celani L; Colafigli M; De Vito A; Mazzitelli M; Dusina A; Durante M; Montagnani F; Rusconi S; Capetti A; Sterrantino G; D'Ettorre G; Di Giambenedetto S;
    HIV Med; 2021 Oct; 22(9):843-853. PubMed ID: 34318591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study.
    Gagliardini R; Baccini M; Modica S; Montagnani F; Zanelli G; Borghetti A; Dreassi E; Lombardi F; Pecorari M; Borghi V; Callegaro A; Micheli V; Lodi MA; Rossetti B; Zazzi M;
    J Glob Antimicrob Resist; 2022 Mar; 28():274-281. PubMed ID: 35092828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: Latest evidence from the literature on their efficacy and safety.
    Cento V; Perno CF
    J Glob Antimicrob Resist; 2020 Mar; 20():228-237. PubMed ID: 31446092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV.
    Dueñas-Gutiérrez C; Buzón L; Pedrero-Tomé R; Iribarren JA; De Los Santos I; De la Fuente S; Pousada G; Moran MA; Moreno E; Ferreira E; Gómez J; Troya J
    Viruses; 2023 Apr; 15(4):. PubMed ID: 37112915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokines assets in PLWH in two-drug dolutergravir based or three-drug antiretroviral regimen.
    Falasca K; Ucciferri C; Di Gasbarro A; Borrelli P; Di Nicola M; Frisenda C; Costantini E; Aielli L; Reale M; Vecchiet J
    BMC Infect Dis; 2024 Jul; 24(1):665. PubMed ID: 38961336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection.
    Deng L; Li C; Chen P; Luo X; Zheng X; Zhou L; Zhou Y; Xia J; Hong Z
    BMC Infect Dis; 2022 Jan; 22(1):17. PubMed ID: 34983415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study.
    Schneider S; Blick G; Burke C; Ward D; Benson P; Felizarta F; Green D; Donovan C; Harper G; Merrill D; Metzner AA; Mycock K; Wallis H; Patarroyo J; Brogan AP; Oglesby A
    Infect Dis Ther; 2024 Apr; 13(4):891-906. PubMed ID: 38570443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durability of doravirine with dolutegravir dual regimen compared with other dolutegravir-based dual combinations.
    Rossotti R; D'Amico F; Bana NB; Nava A; Rezzonico LF; Raimondi A; Fanti D; Chianura LG; Moioli MC; Vismara C; Puoti M
    HIV Med; 2024 Jun; 25(6):675-683. PubMed ID: 38263787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamics of Total and Intact HIV-1 DNA in Virologically Suppressed Patients Switching to DTG-Based or ATV-Based Dual Therapy.
    Dragoni F; Rossetti B; Lombardi F; Spertilli Raffaelli C; Bartolini N; Giammarino F; Moschese D; Di Giambenedetto S; Fabbiani M; De Luca A; Vicenti I; Zazzi M; Saladini F
    J Acquir Immune Defic Syndr; 2022 Dec; 91(4):381-389. PubMed ID: 35969477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shorter Time to Discontinuation Due to Treatment Failure in People Living with HIV Switched to Dolutegravir Plus Either Rilpivirine or Lamivudine Compared with Integrase Inhibitor-Based Triple Therapy in a Large Spanish Cohort.
    Teira R; Diaz-Cuervo H; Aragão F; Castaño M; Romero A; Roca B; Montero M; Galindo MJ; Muñoz-Sánchez MJ; Espinosa N; Peraire J; Martínez E; de la Fuente B; Domingo P; Deig E; Merino MD; Geijo P; Estrada V; Sepúlveda MA; García J; Berenguer J; Currán A
    Infect Dis Ther; 2022 Jun; 11(3):1177-1192. PubMed ID: 35399147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients.
    Hidalgo-Tenorio C; Cortés LL; Gutiérrez A; Santos J; Omar M; Gálvez C; Sequera S; Jesús SE; Téllez F; Fernández E; García C; Pasquau J
    Medicine (Baltimore); 2019 Aug; 98(32):e16813. PubMed ID: 31393412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting.
    Lombardi F; Belmonti S; Moschese D; Fabbiani M; Borghetti A; Ciccullo A; Visconti E; Di Giambenedetto S
    HIV Res Clin Pract; 2022 Dec; 23(1):28-36. PubMed ID: 35758043
    [No Abstract]   [Full Text] [Related]  

  • 14. Similar CD4/CD8 Ratio Recovery After Initiation of Dolutegravir Plus Lamivudine Versus Dolutegravir or Bictegravir-Based Three-Drug Regimens in Naive Adults With HIV.
    Martínez-Sanz J; Ron R; Moreno E; Sánchez-Conde M; Muriel A; López Cortés LF; Blanco JR; Pineda JA; Mena Á; Calzado Isbert S; Moreno S; Serrano-Villar S
    Front Immunol; 2022; 13():873408. PubMed ID: 35432298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiomics plasma effects of switching from triple antiretroviral regimens to dolutegravir plus lamivudine.
    de Lazzari E; Negredo EB; Domingo P; Tiraboschi JM; Ribera E; Abdulghani N; Alba V; Fernández-Arroyo S; Viladés C; Peraire J; Gatell JM; Blanco JL; Vidal F; Rull A; Martinez E
    J Antimicrob Chemother; 2024 May; 79(5):1133-1141. PubMed ID: 38546974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Experience with Dolutegravir-Based Two-Drug Regimens.
    Ward D; Ramgopal M; Riedel DJ; Garris C; Dhir S; Waller J; Roberts J; Mycock K; Oglesby A; Collins B; Dominguez M; Pike J; Mrus J
    AIDS Res Treat; 2020; 2020():5923256. PubMed ID: 32724674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real-world setting in Belgium.
    Nasreddine R; Yombi JC; Darcis G; Florence E; Allard SD; De Scheerder MA; Henrard S; Demeester R; Messiaen P; Ausselet N; Loeckx M; Delforge M; De Wit S;
    HIV Med; 2023 Mar; 24(3):267-278. PubMed ID: 35938381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simplification to dual therapy containing lamivudine and raltegravir or dolutegravir in HIV-infected patients on virologically suppressive antiretroviral therapy.
    Calza L; Colangeli V; Borderi M; Testi D; Granozzi B; Bon I; Re MC; Viale P
    J Antimicrob Chemother; 2020 Nov; 75(11):3327-3333. PubMed ID: 32728708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rildo: Real-World Multicenter Study on the Effectiveness and Safety of Single-Tablet Regimen of Dolutegravir plus Rilpivirine in Treatment-Experienced People Living with HIV.
    Hidalgo-Tenorio C; Vinuesa D; García-Vallecillos C; Muñoz-Medina L; Sequera S; Javier R; López-Ruz MÁ; Sadyrbaeva-Dolgova S; Pasquau J
    Viruses; 2022 Nov; 14(12):. PubMed ID: 36560630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
    Molina JM; Ward D; Brar I; Mills A; Stellbrink HJ; López-Cortés L; Ruane P; Podzamczer D; Brinson C; Custodio J; Liu H; Andreatta K; Martin H; Cheng A; Quirk E
    Lancet HIV; 2018 Jul; 5(7):e357-e365. PubMed ID: 29925489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.